R & D

The ecosystem delivering biopharmaceutical innovation has shifted.

Where global pharma companies had previously discovered, developed and delivered new products from their own labs, now the driving source of innovation is coming from smaller biotechnology and specialty pharma companies, as well as academia. 

We Live Open Science
Our Pipeline
Allergan has an Open Science pipeline powered by 55+ programs in development.
Open Science
Allergan has sought to follow a different R&D path. We embrace an Open Science model that defines the Company’s position.